Category: alkaloid
Aliases: iboga, 12-methoxyibogamine
Iboga alkaloid with anti-addiction interest (suppresses opioid withdrawal and craving). Polypharmacology — NMDA-receptor antagonist, sigma-1/2, kappa- and mu-opioid, SERT, nicotinic — NOT primarily a 5-HT2A drug. CYP2D6 converts it to the long-lived active metabolite noribogaine. Major risk: QT prolongation → torsades / cardiac arrest.
PO: 10.2h
PubChem CID 197060. Anti-addiction "flood" dose ~10–20 mg/kg (≈700–1400 mg/70 kg). PK: Glue 2015 (PMID:25651476) verbatim ibogaine "an elimination half-life of 10.2 hours" — measured in CYP2D6-inhibited (paroxetine-pretreated) subjects where parent accumulates; normal metabolizers convert rapidly to noribogaine (human t½ "28-49 hours", PMID:25279818). 5-HT2A occupancy not authored — it is not a primary ibogaine target.